Healthcare >> CEO Interviews >> April 26, 2005
DAVID LUDVIGSON, President and Chief Executive Officer of Nanogen, Inc.,
joined the company in May 2003 and has served on the Nanogen Board since
1996. Over the last 20 years, he has held key operational positions,
including COO, CFO and VP of Sales and Marketing at leading
biotechnology and technology companies. Most recently, Mr. Ludvigson was
President and Chief Executive Officer of Black Pearl, a leader in event-
based business intelligence software for enterprises. Prior to Black
Pearl, he was President of InterTrust Technologies, a well-respected
digital rights management software company. From 1998 to 2000, he was
Chief Financial Officer and then Chief Operating Officer at Matrix
Pharmaceuticals, a public company focused on developing cancer
therapeutics, where he was responsible for operations, finance and
administration functions. From 1993 to 1996, he was Vice President and
CFO of IDEC, during which time he helped conclude an alliance with
Genentech for Rituxan', a cancer therapeutic, considered one of the most
successful alliances in the biotech industry. Mr. Ludvigson recently
joined the Board of Directors of Argonaut Technologies, a maker of
instruments and chemistry consumables for drug discovery. Mr. Ludvigson
received both a BS and MS degree from University of Illinois, Champaign-
Urbana campus. Profile
and a picture of the things you're doing at the present time.
Mr. Ludvigson: Nanogen was founded in 1993 and went public
